TITLE

Recent advances in understanding and mitigating adipogenic and metabolic effects of antipsychotic drugs

AUTHOR(S)
Gohlke, Julia M.; Dhurandhar, Emily J.; Correll, Christoph U.; Morrato, Elaine H.; Newcomer, John W.; Remington, Gary; Nasrallah, Henry A.; Crystal, Stephen; Nicol, Ginger; Allison, David B.; McCreary, Andrew C.; Jackson, Helen
PUB. DATE
June 2012
SOURCE
Frontiers in Psychiatry;Jun2012, Vol. 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
88074238

 

Related Articles

  • Mechanisms and Genetics of Antipsychotic-Associated Weight Gain. Balt, S. L.; Galloway, G. P.; Baggott, M. J.; Schwartz, Z.; Mendelson, J. // Clinical Pharmacology & Therapeutics;Jul2011, Vol. 90 Issue 1, p179 

    The article discusses the results of recent studies on obesity associated with antipsychotic medications. It states that atypical antipsychotic agents often cause weight gain and metabolic disorders. It discusses the current understanding on the effects of antipsychotic drugs on neural...

  • Reports on Individual Drugs. Griffiths, Jenna; Springuel, Pascale // WHO Drug Information;2001, Vol. 15 Issue 3/4, p152 

    Examines the effects of atypical antipsychotics on the glucose metabolism of schizophrenic patients. Types of atypical antipsychotics; Adverse drug reactions; Characteristics of patients with impaired glucose metabolism.

  • Antipsychotic Drugs for First-Episode Schizophrenia. Salimi, Kayvon; Jarskog, L. Fredrik; Lieberman, Jeffrey A. // CNS Drugs;2009, Vol. 23 Issue 10, p837 

    Increasingly, it is recognized that first-episode schizophrenia represents a critical stage of illness during which the effectiveness of therapeutic interventions can affect long-term outcome. In this regard, the advent of clozapine and subsequent atypical antipsychotic drugs held promise for...

  • Pharmacological Mechanisms Underlying the Association of Antipsychotics with Metabolic Disorders. MIRON, ILEANA CRISTINA; BAROANĂ, VICTORIŢA CĂTĂLINA; POPESCU, FLORICA; IONICĂ, FLORIANA // Fisheries & Aquatic Sciences;Jan2014, Vol. 40 Issue 1, p12 

    Obesity and metabolic syndrome in association with an increased risk of cardiovascular disease and type II diabetes are significant problems that contribute to lower life expectancy of patients with schizophrenia. Understanding the pharmacological mechanisms of the current antipsychotic...

  • Pharmacological Mechanisms Underlying the Association of Antipsychotics with Metabolic Disorders. MIRON, ILEANA CRISTINA; BAROANĂ, VICTORIŢA CĂTĂLINA; POPESCU, FLORICA; IONICĂ, FLORIANA // Current Health Sciences Journal;Jan-Mar2014, Vol. 40 Issue 1, p12 

    Obesity and metabolic syndrome in association with an increased risk of cardiovascular disease and type II diabetes are significant problems that contribute to lower life expectancy of patients with schizophrenia. Understanding the pharmacological mechanisms of the current antipsychotic...

  • Çocuk ve Ergenlerde Atipik Antipsikotik Ä°laçların Metabolik ve Endokrin Yan Etkileri. Çelik, Gonca Gül; Tahiroğlu, Ayşegül; Avcı, Ayşe // Current Approaches in Psychiatry / Psikiyatride Guncel Yaklasiml;2011, Vol. 3 Issue 2, p232 

    Comorbid psychiatric disorders, frequent hospitalization, multiple outpatient treatment, prior history of hypertension, obesity and lipid dysregulation are associated with higher risk of metabolic syndrome in children. Side effects of antipsychotic drugs and their management have recently become...

  • Antipsychotic Drug Treatment for Patients with Schizophrenia: Theoretical Background, Clinical Considerations and Patient Preferences. Nielsen, René Ernst; Nielsen, Jimmi // Clinical Medicine: Therapeutics;2009, Issue 1, p1053 

    The cornerstone in treatment of psychosis is antipsychotic drugs. Treatment options have increased over the years; newer antipsychotic drugs with a proposed increased efficacy regarding negative and cognitive symptoms, but also a shift in side-effects from neurological side-effects to metabolic...

  • Antipsychotic Drugs: Evolving Mechanisms of Action with Improved Therapeutic Benefits. Dean, B.; Scarr, E. // Current Drug Targets - CNS & Neurological Disorders;Jun2004, Vol. 3 Issue 3, p217 

    One of the conundrums of neuropharmacology is to understand the therapeutic mechanisms of action of antipsychotic drugs. Every drug with antipsychotic activity is a dopamine (DA) D2-like receptor antagonist and therefore this function is critical to reducing psychotic symptoms. However, the...

  • Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. Girgis, R R; Javitch, J A; Lieberman, J A // Molecular Psychiatry;Oct2008, Vol. 13 Issue 10, p918 

    The exact therapeutic mechanism of action of antipsychotic drugs remains unclear. Recent evidence has shown that second-generation antipsychotic drugs (SGAs) are differentially associated with metabolic side effects compared to first-generation antipsychotic drugs (FGAs). Their proclivity to...

  • Lipid-Lowering Effects of Tetradecylthioacetic Acid in Antipsychotic-Exposed, Female Rats: Challenges with Long-Term Treatment. Skrede, Silje; Fernø, Johan; Bjørndal, Bodil; Brede, Wenche Rødseth; Bohov, Pavol; Berge, Rolf Kristian; Steen, Vidar Martin // PLoS ONE;Nov2012, Vol. 7 Issue 11, Special section p1 

    Background: Psychiatric patients often require chronic treatment with antipsychotic drugs, and while rats are frequently used to study antipsychotic-induced metabolic adverse effects, long-term exposure has only partially mimicked the appetite-stimulating and weight-inducing effects found in the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics